RHYTHM PHARMACEUTICALS CEO David Meeker's 2022 pay falls 49% to $3.3M
RHYTHM PHARMACEUTICALS reports 2022 executive compensation
By ExecPay News
Published: April 27, 2023
RHYTHM PHARMACEUTICALS reported fiscal year 2022 executive compensation information on April 27, 2023.
In 2022, five executives at RHYTHM PHARMACEUTICALS received on average a compensation package of $1.6M, a 48% decrease compared to previous year.
Average pay of disclosed executives at RHYTHM PHARMACEUTICALS
David P. Meeker, Chief Executive Officer, received $3.3M in total, which decreased by 49% compared to 2021. 65% of Meeker's compensation, or $2.2M, was in option awards. Meeker also received $505K in non-equity incentive plan, $652K in salary, as well as $11K in other compensation.
For fiscal year 2022, the median employee pay was $286,392 at RHYTHM PHARMACEUTICALS. Therefore, the ratio of David P. Meeker's pay to the median employee pay was 12 to one.
Hunter C. Smith, Chief Financial Officer, received a compensation package of $1.2M, which decreased by 47% compared to previous year. 38% of the compensation package, or $460K, was in salary.
Yann Mazabraud, Executive Vice President, Head of International, earned $1.2M in 2022, a 45% decrease compared to previous year.
Jennifer Chien, Executive Vice President, Head of North America, received $1.1M in 2022, which decreases by 48% compared to 2021.
Joseph Shulman, Chief Technical Officer, earned $950K in 2022, a 47% decrease compared to previous year.
Related executives
David Meeker
RHYTHM PHARMACEUTICALS
Chief Executive Officer
Hunter Smith
RHYTHM PHARMACEUTICALS
Chief Financial Officer
Jennifer Chien
RHYTHM PHARMACEUTICALS
Executive Vice President, Head of North America
Yann Mazabraud
RHYTHM PHARMACEUTICALS
Executive Vice President, Head of International
Joseph Shulman
RHYTHM PHARMACEUTICALS
Chief Technical Officer
You may also like
Source: SEC filing on April 27, 2023.